No Data
BridgeBio Pharma Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results.
Sage Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $14.06M Inline
Here Are the Major Earnings After the Close Today
Earnings Scheduled For April 29, 2025
BEIGENE's revenue growth in 2024, narrowing losses, and core products gaining global traction.
① The company achieved a revenue of 27.214 billion yuan for the year, with a year-on-year increase of 56.19%; the net income attributable to shareholders was -4.978 billion yuan, a decrease of 17.38% from the previous year; the net income excluding non-recurring items was -5.379 billion yuan, a year-on-year decrease of 17.38%; ② The revenue share of Baiyueze and Baizean continues to expand, driving the company's revenue growth.
Analyst Expectations For SpringWorks Therapeutics's Future
lightfoot : junk, hook, line and sinker
Wonder-Man : great post. thank you for sharing
Christopher Flint197 : like to learn what a swing trade looks like and when to get in and out.